{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T13:10:07Z","timestamp":1739106607171,"version":"3.37.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,5,17]],"date-time":"2009-05-17T00:00:00Z","timestamp":1242518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00393-009-0437-3","type":"journal-article","created":{"date-parts":[[2009,5,15]],"date-time":"2009-05-15T11:08:27Z","timestamp":1242385707000},"page":"370-379","source":"Crossref","is-referenced-by-count":1,"title":["Anti-CD20-Therapie bei rheumatoider Arthritis","Anti-CD20 therapy in rheumatoid arthritis"],"prefix":"10.1007","volume":"68","author":[{"given":"P.","family":"Roll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,17]]},"reference":[{"key":"437_CR1","first-page":"1999","volume":"S900","author":"Bingham","year":"2008","unstructured":"Bingham C, Looney R, Deodhar A et al (2008) Results from a controlled clinical trial (SIERRA) to evaluate primary and recall responses to immunizations in RA patients treated with rituximab. Arthritis Rheum 58 S9 S900:1999","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR2","first-page":"179","volume":"SII","author":"Breedveld","year":"2006","unstructured":"Breedveld FC, Agrawal SK, Yin M, Ng C (2006) Relationship between clinical response rituximab pharmacokinetics and peripheral B cell levels in rheumatoid arthrits. Ann Rheum Dis 65 SII:179","journal-title":"Ann Rheum Dis 65"},{"key":"437_CR3","first-page":"S180","volume":"56","author":"Burge","year":"2007","unstructured":"Burge D, Chopiak V, Dvoretskiy et al (2007) TRU-015 improves Rheumatoid Arthritis disease Activity in a randomized, double-blind, placebo-controlled, multi-center phase 2 dose ranging trial. Arthritis Rheum 56:S180","journal-title":"Arthritis Rheum"},{"key":"437_CR4","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"437_CR5","first-page":"303","volume":"A368","author":"Cohen","year":"2008","unstructured":"Cohen S, Keystone E, Genovese M et al (2008) Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: Reflex Study. Arthritis Rheum 58 S9 A368:303","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR6","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"De","year":"2002","unstructured":"De Vita S, Zaja F, Sacco S et al (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 46:2029\u20132033","journal-title":"Arthritis Rheum"},{"key":"437_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"Edwards","year":"2001","unstructured":"Edwards JCW, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol 40:205\u2013211","journal-title":"Rheumatol"},{"key":"437_CR8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"Edwards","year":"2004","unstructured":"Edwards JCW, Szczepanski L, Szechinski J et al (2004) Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"437_CR9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite Methotrexate treatment. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"437_CR10","first-page":"302","volume":"A364","author":"Emery","year":"2008","unstructured":"Emery P, Rigby WF, Combe B et al (2008) Efficacy and safety of rituximab as first line biologic therapy in patients with active rheumatoide arthritis: Results of a Phase III randomized controlled study (SERENE). Arthritis Rheum 58 S9 A364:302","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","volume":"56","author":"Finckh","year":"2007","unstructured":"Finckh A, Ciurea A, Brulhart L et al (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417\u20131423","journal-title":"Arthritis Rheum"},{"key":"437_CR12","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","volume":"Suppl3","author":"Furst","year":"2008","unstructured":"Furst DE, Keystone EC, Kirkham B et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases 2008. Ann Rheum Dis 67 Suppl3:iii2\u201325","journal-title":"Ann Rheum Dis 67"},{"key":"437_CR13","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"Genovese","year":"2008","unstructured":"Genovese MC, Kaine JL, Lowenstein MB et al (2008) Ocrelizumab, a humanized Anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 58:2652\u20132661","journal-title":"Arthritis Rheum"},{"key":"437_CR14","doi-asserted-by":"crossref","unstructured":"Genovese MC, Breedveld FC, Emery P et al (2009) Safety of biologic therapy following rituximab treatment in rheumatoid arthrits patients. Ann Rheum Dis [Epub ahead of print]","DOI":"10.1136\/ard.2008.101675"},{"key":"437_CR15","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"Keystone","year":"2007","unstructured":"Keystone E, Fleischmann, Emery P et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthrits. Arthritis Rheum 56:3896\u20133908","journal-title":"Arthritis Rheum"},{"key":"437_CR16","first-page":"303","volume":"A367","author":"Keystone","year":"2008","unstructured":"Keystone EC, Fleischmann RM, Emery P et al (2008) Efficacy and safety of repeat treatment courses of rituximab in RA patients with inadequate response to tumor necrosis factor inhibitors: Long term experience from the Reflex study. Arthritis Rheum 58 S9 A367:303","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","volume":"68","author":"Keystone","year":"2009","unstructured":"Keystone E, Emery P, Peterfy CG et al (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthrits with an inadequate response to tumor necrosis factor inhibitor therapies. Ann Rheum Dis 68:216\u2013221","journal-title":"Ann Rheum Dis"},{"key":"437_CR18","first-page":"S247","volume":"54","author":"Kremer","year":"2006","unstructured":"Kremer JM, Tony HP, Tak PP et al (2006) Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Arthritis Rheum 54:S247","journal-title":"Arthritis Rheum"},{"key":"437_CR19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JSC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883\u2013888","journal-title":"Ann Rheum Dis"},{"key":"437_CR20","first-page":"1212","volume":"S619","author":"Mease","year":"2008","unstructured":"Mease PJ, Cohen S, Gaylis NB et al (2008) Efficacy, safety and dose frequency of retreatment with rituximab in RA: Results from a randomized controlled trial (SUNRISE). Arthritis Rheum 58 S9 S619:1212","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR21","first-page":"S372","volume":"58","author":"Osttergaard","year":"2008","unstructured":"Osttergaard M, Baslund B, Rigby W et al (2008) Ofatumumab, a human CD20 monoclonal antibody, in the treatment of Rheumatoid Arthritis (RA) Subgroup analysis at week 24 from a phase I\/II clinical trial. Arthritis Rheum 58:S372","journal-title":"Arthritis Rheum"},{"key":"437_CR22","unstructured":"Roche Mitteilung an die Medien (19.12.2008) MabThera hemmt Gelenkzerst\u00f6rung bei Patienten mit rheumatoider Arthritis im Fr\u00fchstadium. Phase III-Studie bei nicht mit Methotrexat vorbehandelten Patienten erreicht prim\u00e4ren Endpunkt. http:\/\/www.roche.com."},{"key":"437_CR23","unstructured":"Rote Hand Brief f\u00fcr Rituximab (MabThera) [6.11.2008] Progressive multifokale Leukenzephalopathie (PML) im Zusammenhang mit der Anwendung von MabThera bei Autoimmunerkrankungen einschlie\u00dflich der rheumatoiden Arthritis. http:\/\/www.roche.com"},{"key":"437_CR24","first-page":"301","volume":"A363","author":"Rubbert-Roth","year":"2008","unstructured":"Rubbert-Roth A, Tak PP, Bombardi S et al (2008) Efficacy and safety of various dosing regimens of rituximab in patients with active RA: Results of a phase III randomized study (MIRROR). Arthritis Rheum 58 S9 A363:301","journal-title":"Arthritis Rheum 58 S9"},{"key":"437_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25\u201332","journal-title":"Ann Rheum Dis"},{"key":"437_CR26","first-page":"300","volume":"A361","author":"Van","year":"2008","unstructured":"Van Vollenhofen RF, Emery P, Bingham III CO et al (2008) Long-term safety of rituximab: 6 year follow up of the RA clinical trials and retreatment population. Arthritis Rheum 58 S9 A361:300","journal-title":"Arthritis Rheum 58 S9"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0437-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0437-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0437-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T12:34:11Z","timestamp":1739104451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0437-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0437-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2009,5,17]]}}}